NBI-921352

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

SeizureDevelopmental and Epileptic Encephalopathy

109 competitors in Seizure

#DrugCompanyPhaseTrials

1

Briviact

UCB

Phase 3

122

Afinitor

Novartis

Phase 3

13

Fintepla

IImmedica Pharma AB

Phase 3

34

E2007

Eisai

Phase 3

65

Epsom Salt

FFresenius Kabi Oncology Ltd.

Phase 3

16

Ativan

BBausch Health Americas, Inc.

Phase 3

17

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

18

SPM 929

UCB

Phase 3

39

Valproate Sodium

Sanofi

Phase 3

110

Carisbamate

SSK Life Science, Inc.

Phase 3

4Show 34 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Seizure2 trials

Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

Terminated·Neurocrine Biosciences·Phase 2·NCT05493293·82 enrolled

A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

Completed·Neurocrine Biosciences·Phase 2·NCT05159908·101 enrolled

ART1 trial

Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE

Active, not recruiting·Neurocrine Biosciences·Phase 2·NCT05226780·8 enrolled

Developmental and Epileptic Encephalopathy1 trial

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

Terminated·Neurocrine Biosciences·Phase 2·NCT04873869·8 enrolled

Details

Drug Info

Related News